This page is educational and is not medical advice.
Insulin resistance is a state in which a normal amount of insulin produces a smaller than normal effect in the tissues it acts on, mainly skeletal muscle, the liver and fat tissue. Insulin is released by the pancreas after a meal. It tells muscle to pull glucose out of the blood, tells the liver to stop pushing its stored glucose out, and tells fat tissue to hold on to the fat it already stores.
When those tissues respond weakly, blood glucose would drift upward, so the pancreas compensates by secreting more insulin. For years, that compensation can work well enough that glucose on a routine panel still looks unremarkable while circulating insulin is quietly elevated. This compensatory stage is a core part of how the condition has been defined and described in the clinical literature 1.
Two things follow from that definition. First, insulin resistance is a continuum rather than a switch that flips. Tissues vary in how sensitive they are, and the same person can be more resistant in muscle than in liver, or the reverse. Second, it is a physiological state, not a diagnosis you can read off one number. Reviews of its aetiology describe it as the convergence of genetic background, nutrient excess, tissue lipid handling and immune signalling rather than a single lesion 2.
That is why the useful question is rarely whether someone is resistant or not. It is which drivers are loaded in that particular person, and which of them are modifiable.
Cells become less responsive because the signal that insulin triggers inside them is interrupted somewhere between the receptor and the machinery that moves glucose across the cell membrane. Insulin binds its receptor, the receptor activates a chain of internal messengers, and the end result in muscle and fat is that glucose transporters stored inside the cell move to the surface and let glucose in. Research on insulin signalling and transporter trafficking suggests that the defect in insulin resistance frequently sits in this trafficking step, so the transporters are present but fewer of them reach the cell surface when insulin calls 3.
What interrupts the signal? The most consistently described mechanism involves lipids accumulating inside cells that were never built to store much fat. When fatty acids arrive faster than a muscle or liver cell can burn or safely package them, by-products of lipid metabolism build up and interfere with the internal messengers that insulin depends on. A landmark review of mechanisms describes this lipid interference alongside endoplasmic reticulum stress, mitochondrial changes and inflammatory signalling as overlapping threads rather than competing theories 4.
There is also a self-reinforcing loop. Higher circulating insulin promotes fat storage and suppresses fat release, and a tissue that is already resistant sees more insulin, not less. The liver adds a quirk. It can stay responsive to insulin's fat-building instructions while becoming resistant to insulin's instruction to stop releasing glucose, which helps explain why rising triglycerides and rising fasting glucose often travel together.
Fasting insulin measures how much insulin is circulating after an overnight fast, which is a practical window into how hard the pancreas is working to keep glucose normal. Labs commonly regard roughly 2 to 18 µU/mL as a typical reference range, and ranges vary by lab, assay, age and sex. FitScript's optimal range for fasting insulin is 2 to 5 µU/mL, an optimization target rather than a diagnostic cut-off.
A higher result may reflect greater insulin output to overcome reduced tissue sensitivity. A low result in someone with normal glucose is usually unremarkable. One value is never a diagnosis, and trends matter more than a single draw. The full picture of what the marker measures, how it is collected and what high or low results may reflect lives on the Fasting Insulin guide.
The main drivers are nutrient excess, inactivity, disrupted sleep, chronic stress, inflammation, inherited susceptibility, age and specific hormonal or medication-related causes. They rarely act alone, and most people carry two or three at once. The table below summarises how each one is thought to act and how well supported it is.
| Driver | How it is thought to act | What the evidence suggests |
|---|---|---|
| Sustained energy surplus | More fat delivered to tissues than they can safely store | Strong |
| Low grade chronic inflammation | Immune signalling crosses into insulin signalling pathways | Well described, and bidirectional |
| Genetics and family history | Inherited differences in signalling, fat storage capacity and pancreatic reserve | Clear contribution, not deterministic |
| Age and loss of muscle mass | Less muscle to store glucose, usually alongside less activity | Moderate, heavily confounded by lifestyle |
| Hormonal conditions and certain medications | Hormones or drugs that oppose or blunt insulin's action | Condition specific, assessed by a clinician |
The practical value of this list is that the modifiable rows outnumber the fixed ones.
Body fat affects insulin sensitivity less through total mass and more through where fat ends up when subcutaneous storage runs out of room. Subcutaneous fat under the skin is a comparatively safe warehouse. When intake persistently exceeds what that warehouse can expand to hold, fatty acids spill into the bloodstream and are taken up by tissues that store fat poorly, mainly the liver, skeletal muscle, the pancreas and the fat packed around the abdominal organs.
This is the lipotoxicity model, and reviews of obesity and insulin resistance describe it as a central link between excess adiposity and impaired insulin action 5. Earlier work in the same area set out how lipid overflow, adipose tissue dysfunction and altered signalling molecules released by fat tissue combine to blunt insulin's effect 6.
This explains two things that otherwise look contradictory. Some people carrying a lot of subcutaneous fat retain reasonable insulin sensitivity because their storage capacity is large. Other people who look lean can be markedly insulin resistant because relatively modest fat has settled in the liver and muscle. Storage capacity appears to be partly inherited, which is one route through which family history shows up.
Fat tissue is also an endocrine organ, not inert padding. As it expands and becomes stressed, the mix of signalling molecules it releases shifts in ways that research links to reduced insulin action, and reviews of obesity pathophysiology place this shift alongside immune cell infiltration as a driver rather than a side effect 7. Waist measurement, and markers such as triglycerides, usually track this better than weight alone.
Total energy intake appears to matter most, with food composition shaping how quickly and where the damage accumulates. A sustained energy surplus is the reliable route to filling subcutaneous storage and pushing fat into liver and muscle, and that is the mechanism with the strongest mechanistic support.
Composition is not irrelevant, though. Liquid sugar is absorbed quickly and delivers large fructose loads to the liver, which may favour greater liver fat accumulation than the same energy from other sources. Highly refined, low fibre carbohydrate drives larger glucose and insulin excursions after meals, and repeated large excursions mean more time spent with high circulating insulin. Diets low in fibre and in minimally processed plant foods are associated with poorer glucose handling, though food patterns are hard to isolate from the rest of a person's life.
Alcohol adds energy, is processed by the liver and is associated with liver fat accumulation at higher intakes. Meal timing matters as well, which is covered in the sleep section below.
Two honest caveats belong here. First, no single food causes insulin resistance, and framing it that way misleads. Second, many people with reasonable-looking diets are still insulin resistant because the dominant driver in their case is inactivity, sleep, inherited storage capacity or an untreated hormonal condition. A food log alone cannot tell you which it is. Blood markers can narrow it considerably, which is why intake questions and laboratory data are more useful together than either is alone.
Inactivity matters more than most people expect, because skeletal muscle is the largest single destination for glucose after a meal, and muscle contraction moves glucose into cells through a route that does not require insulin at all. When muscles contract, glucose transporters move to the cell surface independently of the insulin signal, which is why a walk after eating lowers the insulin demand of that meal.
Two separate effects stack. The acute effect lasts roughly a day to two after a session of exercise, during which muscle takes up glucose more readily for a given amount of insulin. The structural effect comes from training over months, which increases muscle mass, mitochondrial capacity and the amount of glucose that can be stored as muscle glycogen. More storage space means less fat spillover and less pressure on insulin.
The inverse holds too. Reducing daily step counts or imposing bed rest measurably reduces insulin sensitivity within days, well before any meaningful change in body weight. That timeline is a useful clue that insulin resistance is a dynamic state rather than a slow structural disease. Research on insulin signalling and transporter trafficking supports the idea that the amount of glucose transporter reaching the muscle cell surface is responsive to both training and inactivity 3.
For most people, the relevant variable is not whether they go to a gym. It is how many hours a day they spend without muscle contraction.
Yes, and the effect appears faster than most people assume. Glucose tolerance follows a daily rhythm. The same meal eaten in the morning and late at night produces different glucose and insulin responses, because the body's internal clock prepares tissues for fuel handling at some times of day and not others.
Reviews of circadian biology and metabolism describe how misalignment between the internal clock and the timing of sleep, light and food is associated with reduced insulin sensitivity, and how clock disruption in laboratory models impairs glucose handling 8. Short sleep duration, fragmented sleep and night shift work are all associated with poorer insulin sensitivity.
The proposed mechanisms overlap. Sleep restriction is associated with higher evening cortisol, altered appetite hormone signalling, more circulating free fatty acids and reduced glucose uptake in muscle. Behaviourally, short sleep also tends to increase intake and reduce activity the following day, so the physiological and behavioural routes reinforce each other.
Obstructive sleep apnoea deserves its own mention. The repeated drops in oxygen during the night are associated with sympathetic activation and impaired glucose handling independently of body weight, and in people with loud snoring, witnessed pauses in breathing or heavy daytime sleepiness, this is worth raising with a clinician rather than filing under poor sleep hygiene.
Late eating is the piece people miss. Pushing most daily energy into the hours when the body is least prepared to handle it is a plausible contributor, and shifting energy earlier may improve glucose measures in some people, though this is not settled.
Stress hormones and inflammation act as amplifiers, and in the case of inflammation the relationship runs in both directions. Cortisol, adrenaline and glucagon are counter-regulatory hormones. Their job is to raise blood glucose, mobilise fatty acids and oppose insulin so fuel is available under threat. That is useful in a short emergency. Sustained elevation, whether from chronic psychological stress, severe illness or certain medical conditions, keeps the body in a fuel-mobilising state while insulin is trying to do the opposite.
Inflammation is better characterised. Expanding and stressed fat tissue attracts immune cells, and the signalling molecules they release activate pathways inside cells that interfere with insulin signalling. A foundational review of this field describes how inflammatory signalling and insulin signalling intersect at shared molecular nodes, and how chronic low grade activation is associated with reduced insulin action 9.
The loop closes because insulin resistance and excess ectopic fat themselves promote inflammatory signalling. That is part of why the state tends to persist once established, and why addressing one driver often moves several markers at once.
Practically, this means chronic infections, autoimmune conditions, poor dental health, heavy alcohol intake, disrupted sleep and persistent psychological stress can all plausibly contribute, even in someone whose diet and training look tidy. None of this means stress alone causes the condition. It means stress and inflammation change how much damage a given diet and activity level produce.
Genetics contributes clearly but does not decide the outcome. Inherited variation appears to influence insulin signalling, pancreatic insulin secretion capacity and, importantly, how much fat a person can store subcutaneously before it spills over into liver and muscle. Reviews of the aetiology of insulin resistance place this inherited background alongside environmental exposure rather than above it 2.
The level of body fat associated with impaired glucose handling also differs between ethnic groups, which is consistent with inherited differences in fat storage capacity and body composition. A practical consequence is that a body weight that looks unremarkable for one person may sit well past another person's storage limit.
Age is partly a proxy for other things. Insulin sensitivity tends to decline across adulthood, but much of that decline travels with falling muscle mass, falling activity, rising visceral fat and changing sex hormone levels. Intrinsic ageing has not been cleanly separated from accumulated lifestyle exposure, and older adults who maintain muscle mass and activity often retain good insulin sensitivity. Puberty and pregnancy both involve physiological, temporary reductions in insulin sensitivity that are expected rather than abnormal.
The sensible reading is that genes and age set how much margin a person has. Behaviour, sleep and body composition determine how much of that margin gets used. Someone with a strong family history is not fated to become insulin resistant, but they generally have less room for the drivers above.
Several medical conditions and prescribed medications are associated with reduced insulin sensitivity, and they are worth ruling in or out rather than assuming lifestyle explains everything. Polycystic ovary syndrome is the most common of these in women of reproductive age, and insulin resistance is a central feature of it in many cases. Conditions involving excess cortisol or excess growth hormone directly oppose insulin's action. Thyroid dysfunction in either direction is associated with altered glucose handling. Fatty liver disease, obstructive sleep apnoea and chronic kidney disease all show associations, often as part of a loop rather than a one-way cause.
Pregnancy produces a physiological reduction in insulin sensitivity, which is why glucose is screened during pregnancy. Low testosterone in men and the hormonal shifts around menopause in women are both associated with changes in body composition and insulin sensitivity, though cause and effect are tangled.
On medications, several classes are associated with reduced insulin sensitivity.
This point matters and so does the caveat. No one should stop or change a prescribed medication based on an article. The prescribing clinician weighs the reason the medication was prescribed against its metabolic effects, and a licensed provider evaluates whether any change is appropriate. Discuss your results and any medication with a clinician or licensed provider before changing anything.
It develops over years in most people but can move measurably in either direction within days. Those two statements are both true because insulin sensitivity has a fast component and a slow component.
The fast component is day-to-day. Restricting sleep, reducing step counts or overfeeding can measurably reduce insulin sensitivity within days, before any structural change in body composition. The same responsiveness works in the other direction, which is why insulin sensitivity improves after a single exercise session and after a few nights of adequate sleep.
The slow component is structural. Filling subcutaneous fat stores, accumulating fat in the liver and muscle, losing muscle mass and developing chronic inflammatory signalling take months to years. Unwinding those changes takes months too. This is also why laboratory results can look better after a week of careful behaviour without the underlying driver having changed much, and why a single result taken after an unusual week can mislead in both directions.
Two implications follow. First, interpret fasting insulin and related markers in the context of the week preceding the draw, including sleep, alcohol, illness and training load. Second, when tracking change, allow enough time for the structural component to respond, and repeat testing rather than relying on one post-intervention value. Trends across repeated measurements carry far more information than any single number.
When it persists, the consequences extend well beyond blood sugar, because insulin acts on lipid handling, blood vessels, the kidneys and the heart as well as on glucose. Reviews of insulin resistance in metabolic disease describe it as a common thread running through fatty liver, abnormal blood lipids, elevated blood pressure and reproductive conditions such as polycystic ovary syndrome 10.
The pattern that usually appears first on a lab panel is metabolic rather than glycaemic. Triglycerides drift up, HDL cholesterol drifts down, liver enzymes may rise, blood pressure creeps, and fasting glucose remains in range because the pancreas is still compensating. Only when secretion can no longer keep pace does glucose climb, which is why glucose-only screening can miss years of change.
Cardiovascular risk is part of the picture independently of glucose. Research links insulin resistance and the high circulating insulin that accompanies it to arterial stiffening and vascular changes that precede overt disease 11. Work on the heart muscle itself describes how insulin resistance and sustained high insulin are associated with structural and functional changes in cardiac tissue 12.
None of this is a prediction about any individual. Insulin resistance is a risk state, not a diagnosis, and many people carry it for years without developing the conditions associated with it. The reason to identify it early is simply that the modifiable drivers respond best before the structural changes accumulate. A suboptimal result is information, not a verdict.
Fasting insulin is most informative when read with glucose, a calculated index and the lipid markers that shift early. Each adds something the others miss.
Fasting Glucose shows whether compensation is still holding. Normal glucose with elevated insulin suggests the pancreas is working harder to deliver a normal-looking result. HOMA-IR combines fasting glucose and fasting insulin into a single index of insulin resistance, which makes it useful for tracking change over time. Triglycerides often move early, because insulin resistance in the liver alters how fat is packaged and released, and the triglyceride to HDL relationship is a widely used reflection of that.
Several other markers add context. HbA1c reflects average glucose over the preceding months and is useful but lags behind insulin. Liver enzymes, particularly ALT, can hint at liver fat. An inflammatory marker such as hs-CRP speaks to the inflammatory driver. Uric acid, sex hormones and thyroid markers matter where a hormonal condition is plausible. Body composition and waist measurement add information no blood test provides.
A grouped Metabolic + Insulin panel exists for exactly this reason, since interpreting these markers together is more informative than chasing one at a time. Testing conditions matter as well. Fasting state, recent exercise, recent illness and alcohol in the preceding days all influence results, so standardising the conditions for repeat draws makes trends readable.
It is worth talking to a clinician whenever results sit outside the standard range, when several markers drift together, or when symptoms suggest something beyond lifestyle. Excessive thirst, frequent urination, unexplained weight loss, marked fatigue or vision changes are worth discussing with a clinician promptly, as are glucose or HbA1c values well above the reference range. Irregular menstrual cycles, difficulty conceiving, loud snoring with daytime sleepiness, or a strong family history of metabolic disease are all reasons to bring the question to a professional rather than managing it alone. Never ignore an out-of-range result, and never stop a prescribed medication without speaking to the prescriber.
On the action side, this guide deliberately stays on causes. The companion guide on how to reverse insulin resistance covers what is worth changing and in what order, and the guide on insulin resistance and weight gain covers the relationship between insulin and body weight, which runs in both directions and is widely misunderstood. Questions about prescription medication belong with a prescribing clinician, who evaluates whether any option is appropriate for an individual.
FitScript is built around testing rather than guessing, with 150+ biomarkers tested per year and interpretation by Atlas, FitScript's AI health advisor, so that drivers like liver fat, inflammation and hormonal contributors can be separated rather than assumed.
Not on its own. Sustained energy surplus is the more consistent driver, because it fills subcutaneous fat stores and pushes fat into the liver and muscle, where it interferes with insulin signalling. Composition still matters at the margins. Liquid sugar and highly refined low fibre carbohydrate produce larger glucose and insulin excursions, and high fructose loads may favour greater liver fat accumulation. Sugar is a contributor, not a sole cause.
Yes. Insulin sensitivity tracks where fat sits more closely than how much fat a person carries overall. Someone with limited inherited capacity to store fat under the skin can accumulate fat in the liver and muscle at a body weight that looks unremarkable. Low muscle mass, inactivity, short sleep and inherited susceptibility all push in the same direction. This is one reason testing fasting insulin alongside glucose gives more information than appearance or weight alone.
Because the pancreas compensates. When tissues respond weakly to insulin, the pancreas secretes more of it to keep blood glucose in range, and for years that compensation succeeds. Glucose only drifts upward once secretion can no longer keep pace. That is why fasting insulin and HOMA-IR often shift before fasting glucose does, and why glucose-only screening can miss a long stretch of metabolic change.
More than most people expect. Restricting sleep can reduce measures of insulin sensitivity within days, before any change in body weight. Reviews of circadian biology describe how misalignment between the internal clock and the timing of sleep, light and food is associated with impaired glucose handling. Shift work and late eating show similar associations. Obstructive sleep apnoea is separately associated with poorer glucose handling and is worth raising with a clinician.
Inherited variation contributes but does not decide the outcome. Genes appear to influence insulin signalling, pancreatic insulin secretion capacity and how much fat a person can store subcutaneously before it spills into liver and muscle. The level of body fat associated with impaired glucose handling also differs between ethnic groups. A strong family history generally means less metabolic margin, not an inevitable result.
Stress acts as an amplifier rather than a sole cause. Cortisol and adrenaline are designed to raise blood glucose and mobilise fatty acids, which directly opposes insulin's action. Sustained elevation from chronic stress, illness or certain conditions keeps the body in a fuel-mobilising state. Stress also tends to worsen sleep, intake and activity, so the physiological and behavioural routes reinforce each other. It changes how much effect a given diet and activity level produce.
Fasting insulin and HOMA-IR, which combines fasting insulin with fasting glucose, usually shift earlier than glucose or HbA1c. Triglycerides and HDL cholesterol often move early too, because liver insulin resistance changes how fat is packaged and released. Liver enzymes such as ALT can hint at liver fat, and an inflammatory marker such as hs-CRP speaks to the inflammatory driver. Reading these together is far more informative than any single marker.
It usually accumulates over years, but it has a fast component too. Restricting sleep, cutting daily step counts or overfeeding can measurably reduce insulin sensitivity within days, before body composition changes. The structural side, meaning liver and muscle fat, muscle loss and chronic inflammatory signalling, takes months to years to build and months to unwind. That split is why repeat testing beats a single value.
The association does not mean the medication is wrong for that person. The prescribing clinician weighs the reason it was prescribed against its metabolic effects, and a licensed provider evaluates whether any change is appropriate. Never stop or adjust a prescription based on an article.